ttps://mpnresearchfoundation.org/news/skin-cancer-awareness-month-non-melanoma-skin-cancer-and-mpns/
Skin Cancer Awareness Month: Non-melanoma skin cancer and MPNs
image001.png
May is Skin Cancer Awareness Month. Research shows a link between skin cancers and MPNs. Diligent screening is crucial for those living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
Skin cancers, particularly non-melanomas, offer an example of how quickly and impactfully research can move to action that saves lives.
A recently published study in the journal Blood (Alex Rampatos et.al) followed 90 MPN patients who developed non-melanoma skin cancers (NMSCs) while receiving ruxolitinib therapy, across 18 treatment centers in the United Kingdom. What was learned can have an immediate, potentially life-saving effect on skin cancer prevention and outcomes.
In this specific study, NMSCs were the primary cause of death in 34.3% of patients, which exceeded the percentage of deaths due to myelofibrosis (MF) progression. It is still unclear exactly why these skin cancers are more insistent in people with MPNs; only additional research will drive us deeper into the answers. The authors suggest it may be related, at least in part, to ruxolitinib’s immunosuppressive activity.
In conclusion, Alex Rampatos et al stated, “Our study highlights the aggressive nature of NMSCs in ruxolitinib-treated patients with MPN[s], the importance of counseling patients about the risk of skin cancer before starting ruxolitinib, and a requirement for close dermatological monitoring on treatment.”